Sokolowski P - Search Results

1

Seizure Semiology in Antibody-Associated Autoimmune Encephalitis.

Kaaden T, Madlener M, Angstwurm K, Bien CG, Bogarin Y, Doppler K, Finke A, Gerner ST, Reimann G, Häusler M, Handreka R, Hellwig K, Kaufmann M, Kellinghaus C, Koertvelyessy P, Kraft A, Lewerenz J, Menge T, Paliantonis A, von Podewils F, Prüss H, Rauer S, Ringelstein M, Rostásy K, Schirotzek I, Schwabe J, Sokolowski P, Suesse M, Sühs KW, Surges R, Tauber SC, Thaler F, Bergh FT, Urbanek C, Wandinger KP, Wildemann B, Mues S, Zettl U, Leypoldt F, Melzer N, Geis C, Malter M, Kunze A; and the Generate study group. Kaaden T, et al. Among authors: sokolowski p. Neurol Neuroimmunol Neuroinflamm. 2022 Oct 20;9(6):e200034. doi: 10.1212/NXI.0000000000200034. Print 2022 Nov. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 36266054 Free PMC article.

2

Methionine metabolism and phenotypic variability in X-linked adrenoleukodystrophy.

Linnebank M, Kemp S, Wanders RJ, Kleijer WJ, van der Sterre ML, Gärtner J, Fliessbach K, Semmler A, Sokolowski P, Köhler W, Schlegel U, Schmidt S, Klockgether T, Wüllner U. Linnebank M, et al. Among authors: sokolowski p. Neurology. 2006 Feb 14;66(3):442-3. doi: 10.1212/01.wnl.0000196491.42058.6f. Neurology. 2006. PMID: 16476952

3

Genetic variations and humoral immune responses to myelin oligodendroglia glycoprotein in adult phenotypes of X-linked adrenoleukodystrophy.

Schmidt S, Marrosu GM, Kölsch H, Haase CG, Ferenczik S, Sokolowski P, Köhler W, Schmidt M, Papassotiropoulos A, Heun R, Grosse-Wilde H, Klockgether T. Schmidt S, et al. Among authors: sokolowski p. J Neuroimmunol. 2003 Feb;135(1-2):148-53. doi: 10.1016/s0165-5728(02)00445-9. J Neuroimmunol. 2003. PMID: 12576235

4

Adrenal steroids in adrenomyeloneuropathy. Dehydroepiandrosterone sulfate, androstenedione and 17alpha-hydroxyprogesterone.

Wichers-Rother M, Grigull A, Sokolowski P, Stoffel-Wagner B, Köhler W. Wichers-Rother M, et al. Among authors: sokolowski p. J Neurol. 2005 Dec;252(12):1525-9. doi: 10.1007/s00415-005-0908-7. J Neurol. 2005. PMID: 16362829

5

The cystathionine beta-synthase variant c.844_845ins68 protects against CNS demyelination in X-linked adrenoleukodystrophy.

Linnebank M, Semmler A, Kleijer WJ, van der Sterre ML, Gärtner J, Fliessbach K, Sokolowski P, Köhler W, Schlegel U, Klockgether T, Wanders RJ, Schmidt S, Wüllner U, Kemp S. Linnebank M, et al. Among authors: sokolowski p. Hum Mutat. 2006 Oct;27(10):1063-4. doi: 10.1002/humu.9459. Hum Mutat. 2006. PMID: 16941496

6

X-linked adrenomyeloneuropathy associated with 14 novel ALD-gene mutations: no correlation between type of mutation and age of onset.

Wichers M, Köhler W, Brennemann W, Boese V, Sokolowski P, Bidlingmaier F, Ludwig M. Wichers M, et al. Among authors: sokolowski p. Hum Genet. 1999 Jul-Aug;105(1-2):116-9. doi: 10.1007/s004399900090. Hum Genet. 1999. PMID: 10480364

7

An X-linked gene involved in androgenetic alopecia: a lesson to be learned from adrenoleukodystrophy.

König A, Happle R, Tchitcherina E, Schaefer JR, Sokolowski P, Köhler W, Hoffmann R. König A, et al. Among authors: sokolowski p. Dermatology. 2000;200(3):213-8. doi: 10.1159/000018385. Dermatology. 2000. PMID: 10828629

8

Proceedings of the 4th International Workshop of the Adrenoleukodystrophy International Research Group (ALD-IRG), University of York, 3 September 1998.

Alger S, Green A, Köhler W, Sokolowski P, Moser H. Alger S, et al. Among authors: sokolowski p. J Inherit Metab Dis. 2000 Jul;23(5):449-52. doi: 10.1023/a:1005604012362. J Inherit Metab Dis. 2000. PMID: 10947198 No abstract available.

9

Evaluation of the preventive effect of glyceryl trioleate-trierucate ("Lorenzo's oil") therapy in X-linked adrenoleukodystrophy: results of two concurrent trials.

Moser HW, Raymond GV, Koehler W, Sokolowski P, Hanefeld F, Korenke GC, Green A, Loes DJ, Hunneman DH, Jones RO, Lu SE, Uziel G, Giros ML, Roels F. Moser HW, et al. Among authors: sokolowski p. Adv Exp Med Biol. 2003;544:369-87. doi: 10.1007/978-1-4419-9072-3_47. Adv Exp Med Biol. 2003. PMID: 14713253 Clinical Trial. No abstract available.

10

Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Cree BAC, Cutter G, Wolinsky JS, Freedman MS, Comi G, Giovannoni G, Hartung HP, Arnold D, Kuhle J, Block V, Munschauer FE, Sedel F, Lublin FD; SPI2 investigative teams. Cree BAC, et al. Lancet Neurol. 2020 Dec;19(12):988-997. doi: 10.1016/S1474-4422(20)30347-1. Epub 2020 Oct 23. Lancet Neurol. 2020. PMID: 33222767 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

32 results

Search Page